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The treatment of visceral leishmaniasis (VL) is poorly standardized in Italy in spite of the existing evidence. All consecutive pa-
tients with VL admitted at 15 Italian centers as inpatients or outpatients between January 2004 and December 2008 were retro-
spectively considered; outcome data at 1 year after treatment were obtained for all but 1 patient. Demographic characteristics,
underlying diseases, diagnostic procedures, treatment regimens and outcomes, as well as side effects were recorded. A confirmed
diagnosis of VL was reported for 166 patients: 120 (72.3%) immunocompetent, 21 (12.6%) patients with immune deficiencies
other than HIV infection, and 25 (15.1%) coinfected with HIV. Liposomal amphotericin B (L-AmB) was the drug almost univer-
sally used for treatment, administered to 153 (92.2%) patients. Thirty-seven different regimens, including L-AmBwere used. The
mean doses were 29.4 7.9 mg/kg in immunocompetent patients, 32.9 8.6 mg/kg in patients with non-HIV-related immuno-
deficiencies, and 40.8 6.7 mg/kg in HIV-infected patients (P< 0.001). The mean numbers of infusion days were 7.8 3.1 in
immunocompetent patients, 9.6 3.9 in non-HIV-immunodeficient patients, and 12.0 3.4 in HIV-infected patients (P<
0.001). Mild and reversible adverse events were observed in 12.2% of cases. Responsive patients were 154 (93.3%). Successes were
98.4% among immunocompetent patients, 90.5% among non-HIV-immunodeficient patients, and 72.0% among HIV-infected
patients. Among predictors of primary response to treatment, HIV infection and age held independent associations in the final
multivariate models, whereas the doses and duration of L-AmB treatment were not significantly associated. Longer treatments
and higher doses of L-AmBwere not able to significantly modify treatment outcomes either in the immunocompetent or in the
immunocompromised population.
Visceral Leishmaniasis (VL) in the Mediterranean basin is azoonotic disease caused by Leishmania infantum (1). It is the
only vector-borne disease present in all Mediterranean countries,
with an incidence of symptomatic cases ranging from 5 to 200 for
each country, with Italy being close to the upper limit in recent
years (2). Overt clinical disease with typical features (high fever,
anemia, splenomegaly, hypergammaglobulinemia, and wasting
syndrome) is common in immunocompetent adults and children
(3–5), whereas immunocompromised patients often present
lower rates of response to treatment and atypical disease features.
These include organ transplant recipients, patients with advanced
HIV disease or CD4 T-cell idiopathic deficiency, hematological
malignancies, and patients on long-term steroids or monoclonal
antibody treatments (6–9).
In spite of several treatment options (pentavalent antimony
salts, paramomycin, pentamidine, amphotericin B formulations,
and miltefosine), treatment of VL is still a complex and debated
issue, since the use of each of drug poses different problems either
related to limited efficacy or to potential serious adverse effects or
to costs (10–23). Consensus recommendations from the World
Health Organization (WHO) recognized in 2010 the prevalent use
of liposomal amphotericin B (L-AmB) as the first choice for VL
caused by Leishmania infantum, although they did not shed light
on the great variety of administration schedules used (24). Indeed,
several clinical trials demonstrated 90 to 98% efficacy of L-AmB in
immunocompetent patients, using a total dose of 18 to 21 mg/kg
(14, 25). As a consequence, U.S. regulatory agencies recommend 3
mg/kg on days 1 to 5, 14. and 21 and a total dose of 21 mg/kg (26).
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For pediatric patients, current recommendations indicate L-AmB
at a dose of 10 mg/kg/day for 2 consecutive days, with the yield of
similarly high response rates (27). Finally, in HIV-infected pa-
tients with VL, the WHO and the U.S. Food and Drug Adminis-
tration recommend a total dose of 40 mg of L-AmB/kg.
In spite of such evidence and recommendations, L-AmB for VL
is not yet reimbursable in Italy, and it is widely prescribed “off
label.” This retrospective investigation was endorsed by the Na-
tional Society for Infectious and Tropical Diseases of Italy
(SIMIT) in 2009 to gather further information on the epidemiol-
ogy, clinical features, and therapeutic options in use for patients
with VLat several Italian centers.
MATERIALS AND METHODS
The steering committee of the present study was instituted by the SIMIT
central board early in 2009, based on the proposal of the Abruzzo regional
board. Each infectious disease or pediatric unit adhering to SIMIT (146
units) was contacted individually and asked to participate. Local ethical
committees were notified whenever a unit joined the study, in accordance
with Italian rules for observational investigations. Centers adhering in the
retrospection were requested to collect data relative to all consecutive
patients diagnosed with VL since 2004 through 2008, with the aid of an
electronic datasheet, according with a questionnaire prepared by the
steering committee and approved by all of the participating centers. For all
included patients, follow-up data up to 1 year after treatment completion
were requested. The diagnosis of VL was based on the presence of amas-
tigotes in bone marrow (BM) specimens or other tissue specimens at
microscopic examination in the majority of cases; in a few cases, it was
based on positive serological tests with indirect immunofluorescence
and/or enzyme-linked immunosorbent assays for leishmanial antibodies,
together with positive results of leishmania PCR assays on bone marrow
aspirates or peripheral blood. The following variables were requested:
demographics (age, sex, ethnicity, and region of origin); year of VL diag-
nosis, HIV status, CD4 T-cell counts, both at nadir and enrollment, anti-
retrovirals used for HIV-infected patients, other immunodeficiencies,
and/or comorbidities; hemoglobin levels, white blood cell (WBC) counts,
platelet counts, serum transaminases, serum albumin; type and schedule
of drug(s) used for treatment of VL; treatment of relapse(s); support ther-
apies (RBC transfusions and albumin infusions); adverse events recorded
at any stage during treatment or follow-up; and treatment outcomes
(healing, relapse, and death). The primary outcome of treatment was
defined as the clinical cure of VL, that is, the absence of relapses 1 year after
treatment completion; this included both successes obtained after first
line treatment and those gained after retreatment of relapsers. Multivari-
able logistic regression analyses were used to evaluate potential indepen-
dent predictors of failure to first line treatment, which was the dependent
variable. Age and gender were included into regression models a priori,
along with any other possible significant variable, selecting in a stepwise
forward process. For continuous covariates for which a defined threshold
has been indicated in the literature (for example, platelets [PLT] 50 for
severe thrombocytopenia), we tested the inclusion of both the continuous
and the categorical form and selected the one that was included in the
model with highest pseudo or adjusted R2 values. All variables not in-
cluded into the final models were not significant. Overall, only two sub-
jects with one missing data in one of the variables were excluded from
multivariate models. Thus, no missing data imputation technique was
adopted. The results of the logistic analysis are presented as odds ratios
(OR) and 95% confidence intervals (CI). Statistical significance was de-
fined as a two-sided P value of 0.05 for all analyses, which were per-
formed using STATA 10.1 (Stata Corp., College Station, TX).
RESULTS
Only 113 of the 146 infectious disease or pediatric units adhering
to SIMIT answered to our request after the second notification.
Thirty-two centers replied they had no cases to contribute over the
requested time span. Fifty-five additional centers replied they
were unwilling (28) or unable (23) to participate. Twelve centers
did not provide data after adhering to the survey. As a conse-
quence, 15 Italian centers from 14 Italian towns contributed all of
their retrospective data on patients diagnosed with VL between
2004 and 2008, stating that they were consecutively collected. A
confirmed diagnosis of VL was reported for 166 patients (145 of
European descent). Follow-up data at 1 year after treatment were
provided for all but one patient. The final sample included 120
(72.3%) immunocompetent patients, 21 (12.6%) patients with
immunodeficiencies other than HIV infection, and 25 (15.1)
HIV-coinfected patients (Table 1).
Clinical characteristics and diagnosis. Mean hemoglobin val-
ues at diagnosis were 9.2  2.0 g/dl (range, 4.8 to 16 g/dl), the
mean WBC counts were 3,385  1,978/mm3 (range, 400 to
12,700/mm3), the mean platelet counts were 116,027  58,466/
mm3 (range, 4,500 to 301,000/mm3), and the mean serum albu-
min lavel was 3.2 0.8 g/dl, with 13% of the patients presenting
values of2.5 g/dl. All 166 patients had a definite diagnosis of VL;
males predominated (65.1%), the mean age was 34.9 24.3 years,
with 49 (29.5%) patients aged 18 years. The mean age signifi-
cantly differed in the three groups considered: 29.8 25.3 years in
the 120 immunocompetent patients, 40.8  9.0 years in the 25
HIV-infected patients, and 57.4  15.8 years in the 21 patients
with immunodeficiencies other than HIV (P  0.001, Table 1).
Among the HIV-infected patients included, the mean nadir CD4
T-cell counts were 28.9  18.9 cells/mm3 (range, 1 to 60/mm3)
and the current CD4 T-cell counts at the time of diagnosis of VL
were 125.4 180.7 cells/mm3 (range, 7 to 855/mm3). Eight HIV
patients (32%) were naive to antiretrovirals at the time of VL
diagnosis. Among the patients diagnosed with other immunode-
ficiencies before VL, nine had hematological malignancies, four
TABLE 1 Demographic and selected clinical characteristics of 166
patients with VLa
Characteristic No. of patients (%)
Male 108 (65)
Immunocompetent 120 (72.3)
HIV positive 25 (15)
Hematological malignancy 9 (5.4)
Transplant recipients 5 (3.0)
Long-term steroid treatment 4 (2.4)
Methotrexate treatment 2 (1.2)
Splenectomy 1 (0.6)
With comorbidities
None 116 (69.9)
Multiple 12 (7.2)
Hepatitis 11 (6.6)
Cardiovascular diseases 6 (3.6)
Diabetes 5 (3.0)
Rheumatologic diseases 6 (3.6)
Chronic renal failure 3 (1.8)
COPD 3 (1.8)
Sepsis 2 (1.2)
Pneumonia/TB 2 (1.2)
Thyroid diseases 1 (0.6)
a The mean age of the patients the standard deviation was 34.9 24.3 years (range, 1
to 85 years). COPD, chronic obstructive pulmonary disease; TB, tuberculosis.
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had received bone marrow transplants, one had a renal transplant,
one had undergone a splenectomy, six had a diagnosis of rheuma-
toid arthritis. Among these latter individuals, four had been
treated with long-term steroids (2 months). and two had been
treated with methotrexate. Patients without comorbidities were
116 (69.9%, Table 1).
Direct examination of BM smears and serological tests were
performed in nearly all of the 166 enrolled patients, whereas qual-
itative PCR amplifications from BM cells or blood were per-
formed in approximately half of the cases (Table 2).
The distribution of patients as to the Italian region of origin
was in good agreement with that observed in other series, in spite
of underrepresentation of sites from regions usually reporting
cases. Sicily had the highest number of cases throughout the study
period. Cases of VL decreased steadily in immunocompetent
hosts during the 5 years of observation, from 41 cases in 2004 to 13
in 2008, whereas they remained constant in immunocompro-
mised hosts.
Treatment regimens and outcomes. Twenty-seven (16.3%)
patients needed blood transfusions and/or albumin infusions
early after diagnosis. L-AmB was the most widely used treatment
drug (153 cases, 92.2%), followed by colloidal dispersion of am-
photericin B (7 cases, 4.2%) and antimonial derivatives (6 cases,
3.6%). The mean cumulative doses of L-AmB were 29.4  7.9
mg/kg in immunocompetent patients, 32.9  8.6 mg/kg in pa-
tients with non-HIV-related immunodeficiencies, and 40.8 6.7
mg/kg in HIV-infected patients (P 0.001). The mean numbers
of infusion days were 7.8  3.1 in immunocompetent patients,
9.6 3.9 in non-HIV-immunodeficient patients, and 12.0 3.4
in HIV-infected patients (P 0.001). Thirty-seven different reg-
imens, including L-AmB were used, three of which accounted for
67 (43.8%) of the treatments: (i) 3 mg/kg/day for 15 days, repeated
in a single dose after 5 and 30 days (22 patients), (ii) 3 to 4 mg/kg/
day for 6 to 7 days (22 patients), and (iii) 3 mg/kg/day for 5 days,
repeated in a single dose after 5 days (23 patients). The longest
treatment prescribed included 10 consecutive 3-mg/kg daily doses
of L-AmB, followed by 10 additional doses, used in a single patient
with HIV infection. Patients responsive to treatment were 154
(93.3%) among the 165 evaluable patients, for which a follow-up
of at least 1 year after treatment completion was available. Suc-
cesses included 117 (98.3%) among the 119 immunocompetent
patients, 19 (90.5%) among the 21 non-HIV-immunodeficient
patients, and 18 (72.0%) among the 25 HIV-infected patients
(Table 3). Primary nonresponses were rare overall: two in immuno-
competent patients (1.6%), two (9.5%) among the non-HIV-immu-
nodeficient patients, and three (12%) among the HIV patients (Table
3). Among the 11 relapsers, all five immunocompetent patients were
rescued after retreatment, versus two (33.3%) of the six retreated HIV
patients (Table 3). Nonresponders and relapsers were exposed to
higher cumulative doses than patients cured (37.4 9.4 mg versus
30.9 8.5 mg, P 0.004). No severe adverse events were reported.
Side effects were recorded in 12.2% of patients, without significant
differences among the three groups of patients. None of the side ef-
fects affected the duration of treatment. Most were mild, including
nausea (2.4%), rash (1.8%), diarrhea (1.8%), headache (1.8%), mild
hypokaliemia (0.6%), and mild hypertransaminasemia (0.6%). Mild
and reversible increases in serum creatinine were reported in four
patients (2.4%), three among immunocompetent patients, and one
in a non-HIV-immunodeficient patient. Side effects were more fre-
quent in HIV-negative patients receiving higher doses of L-AmB
(21.6% versus 8.8%, P 0.04); the frequency of side effects did not
differ, however, among patients undergoing retreatment of relapses
(8.3% versus 12.5%, P 0.6).
We searched for factors associated with failure to respond to
first-line treatment. In univariate analyses, HIV infection, types of
other immune deficiency, age, gender, hemoglobin, platelet
counts, serum albumin, transaminases, the presence of comor-
bidities, the length of treatment, the total L-AmB dose, and ad-
verse events were investigated. The final logistic regression model
indicated that the only independent predictors of treatment fail-
ure were HIV infection (OR 12.14, 95% CI 2.75 to 53.65, P
0.001) and age (OR 1.06 for each 1-year increase, 95% CI 1.01
to 1.10, P 0.008) (Table 4).
DISCUSSION
We set up the present investigation to shed light on the critical
issue of treatment of VL in Italy. Our dataset was therefore mainly
TABLE 2 Tests performed for VL diagnosis, with the relative
proportions of positive tests
Diagnostic method
No. (%) of tests
Total Positive
Bone marrow 160 (96.4) 136 (85.0)
Serological tests 153 (92.2) 127 (83.0)
Qualitative PCR 65 (39.1) 58 (89.2)
Quantitative PCR 2 (1.2) 2 (100)
TABLE 3 Proportions of responders to first-line treatment and
retreatment, as stratified by immune status
Response typea
No. (%) of patients
Immunocompetent
(n 119)
Non-HIV
immunodeficient
(n 21)
HIV
coinfected
(n 25)
Primary response 117 (98.3) 19 (90.5) 22 (88)
Nonresponders 2 (1.6) 2 (9.5) 3 (12)
Relapsers 5/117 (4.3) 6/22 (27.2)
Responders to
retreatment
5/5 (100) 2/6 (33.3)
Overall responders 117 (98.3) 19 (90.5) 18 (72)
a Primary response refers to patients who responded to their first treatment cycle.
Nonresponder patients did not respond to their first treatment cycle. Relapsers refers to
patients who had a recurrence of VL after a favorable response to their first-line
treatment. Responders to retreatment refers to patients who responded to the second
line of therapy after relapsing. Overall responders represents the total number of
patients who responded to either first- or second-line therapy.
TABLE 4 Final logistic regression model for predictors of primary
treatment failure
Variable
Failure
PaOR 95% CI
HIV status 12.14 2.7–53.6 0.001
Sex 1.77 0.4–7.2 0.4
Length of treatment 1.11 0.28–4.3 0.9
Age 1.06 1.014–1.1 0.008
PLT 0.99 0.98–1.0 0.5
Side effects 0.32 0.3–3.0 0.3
a Logistic model with 164 observations; P value for the goodness of fit 0.17; area
under the ROC curve 0.8523.
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oriented to monitor how patients were treated around Italy. In the
final sample collected, males predominated, adults were more nu-
merous than children (who nevertheless represented approxi-
mately one-third of the study population), and only a small pro-
portion of the examined patients were coinfected with HIV. These
findinsg are is in line with previous data showing that the inci-
dence of VL decreased in HIV-infected patients after the introduc-
tion of combination antiretroviral therapy (HAART) in southern
Europe (6, 29–31). Nearly one-third of the 25 HIV-infected pa-
tients were naive to HAART when VL was diagnosed, VL being the
index opportunistic infection in late AIDS presentation (data not
shown). Failures were more frequent in HIV patients with lower
nadir CD4 counts (55.5  40.3 versus 172  221, P  0.1),
whereas HIV suppression by HAART was not protective, a finding
in line with similar data in the literature (2, 7).
In the search for factors associated with the failure of first-line
treatment, the final logistic-regression model indicated that the
only independent predictors were HIV infection and older age,
the first reflecting, as discussed above, the profound immune im-
balance determined by CD4 T-cell depletion (32). The pin-
pointed significance of age was in agreement with another report
showing a 5-fold-greater risk of relapse in African patients older
than 45 years and treated with antimonial derivatives (28). Our
study documented that L-AmB, the first choice for the treatment
of VL in high-income countries, was by far the most frequently
drug used at all sites participating in the present retrospection, in
spite of the need of “off-label” prescription. In the absence of
specific local regulatory indications, a variety of L-AmB-based
regimens were used. The data from the present study show a
98.4% efficacy of L-Amb in immunocompetent patients, in good
agreement with most trials reporting 90 to 98% efficacy, with a
total dose of 18 to 21 mg/kg (33, 34). In our sample, the mean
cumulative dose of L-AmB used in immunocompetent patients
was significantly lower than in HIV-infected patients, which is in
line with other studies and most international guidelines, recom-
mending an extended course of L-AmB and a total dose of up to 40
mg/kg in HIV/VL coinfection (14, 33, 34). Indeed, although no
severe adverse events were reported, higher doses and longer treat-
ments of L-AmB were associated with a modest increase in low-
grade toxicity in HIV-negative patients. We therefore suggest that,
in view of the high success rates and limited adverse reactions
observed both in the present and in other published investiga-
tions, regulatory Italian authorities should register the best sched-
ules of L-AmB for treatment of VL, even in the absence of further
studies, to avoid unnecessary over dosage of L-Amb-B in this set-
ting (16, 33–35). In conclusion, our study adds evidence to the
efficacy and appropriateness of current treatment schedules of
L-AmB for VL in both immunocompetent and immunocompro-
mised patients.
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